Following up on a successful mid-stage study for the AMD eye drug lampalizumab, Genentech has triggered a pair of Phase III studies to see if it can extend its blockbuster-making R&D rep beyond the cancer drug sphere.

…read more

Source: Roche’s Genentech triggers its PhIII program for blockbuster AMD contender


0 No comments